Xilio Therapeutics Inc (NASDAQ: XLO)’s stock price has dropped by -9.03 in relation to previous closing price of 1.44. Nevertheless, the company has seen a gain of 32.32% in its stock price over the last five trading days. globenewswire.com reported 2024-10-30 that WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024.
Is It Worth Investing in Xilio Therapeutics Inc (NASDAQ: XLO) Right Now?
XLO has 36-month beta value of -0.21. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for XLO is 21.31M, and currently, short sellers hold a 0.49% ratio of that float. The average trading volume of XLO on November 06, 2024 was 224.08K shares.
XLO’s Market Performance
XLO stock saw an increase of 32.32% in the past week, with a monthly gain of 63.75% and a quarterly increase of 52.06%. The volatility ratio for the week is 18.22%, and the volatility levels for the last 30 days are 12.87% for Xilio Therapeutics Inc (XLO). The simple moving average for the past 20 days is 33.91% for XLO’s stock, with a 43.70% simple moving average for the past 200 days.
Analysts’ Opinion of XLO
Many brokerage firms have already submitted their reports for XLO stocks, with Chardan Capital Markets repeating the rating for XLO by listing it as a “Buy.” The predicted price for XLO in the upcoming period, according to Chardan Capital Markets is $7 based on the research report published on December 21, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see XLO reach a price target of $36. The rating they have provided for XLO stocks is “Buy” according to the report published on January 10th, 2022.
Raymond James gave a rating of “Outperform” to XLO, setting the target price at $31 in the report published on November 16th of the previous year.
XLO Trading at 51.39% from the 50-Day Moving Average
After a stumble in the market that brought XLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.48% of loss for the given period.
Volatility was left at 12.87%, however, over the last 30 days, the volatility rate increased by 18.22%, as shares surge +74.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.29% upper at present.
During the last 5 trading sessions, XLO rose by +32.32%, which changed the moving average for the period of 200-days by +97.05% in comparison to the 20-day moving average, which settled at $0.9783. In addition, Xilio Therapeutics Inc saw 138.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at XLO starting from GILEAD SCIENCES, INC., who purchase 485,250 shares at the price of $0.76 back on Apr 02 ’24. After this action, GILEAD SCIENCES, INC. now owns 7,345,473 shares of Xilio Therapeutics Inc, valued at $368,790 using the latest closing price.
Atlas Venture Fund XI, L.P., the 10% Owner of Xilio Therapeutics Inc, sale 733 shares at $0.64 during a trade that took place back on Feb 08 ’24, which means that Atlas Venture Fund XI, L.P. is holding 2,019,563 shares at $469 based on the most recent closing price.
Stock Fundamentals for XLO
Current profitability levels for the company are sitting at:
- -12.68 for the present operating margin
- 0.66 for the gross margin
The net margin for Xilio Therapeutics Inc stands at -12.46. The total capital return value is set at -1.3. Equity return is now at value -130.03, with -71.92 for asset returns.
Based on Xilio Therapeutics Inc (XLO), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -2.0. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is -222.35.
Currently, EBITDA for the company is -77.23 million with net debt to EBITDA at 1.02. When we switch over and look at the enterprise to sales, we see a ratio of -1.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.02.
Conclusion
To put it simply, Xilio Therapeutics Inc (XLO) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
